1. Name of the medicinal product
Asda Flu-Max All-In-One Chesty Cough & Cold powder for oral solution

Boots Flu-Max All-In-One Chesty Cough & Cold powder for oral solution

Galpharm Flu-Max All-In-One Chesty Cough & Cold powder for oral solution

Lloyds Pharmacy Flu-Max All-In-One Chesty Cough & Cold powder for oral solution

Morrisons Flu-Max All-In-One Chesty Cough & Cold powder for oral solution

Sainsbury's Flu-Max All-In-One Chesty Cough & Cold powder for oral solution

Superdrug Flu-Max All-In-One Chesty Cough & Cold powder for oral solution

Tesco Flu-Max All-In-One Chesty Cough & Cold powder for oral solution

Wilko Flu-Max All-In-One Chesty Cough & Cold powder for oral solution

2. Qualitative and quantitative composition

Active Ingredient
 mg/Sachet
 
Paracetamol
 1000
 
Guaifenesin
 200
 
Phenylephrine hydrochloride
 12.2
 

This product also contains the excipients sucrose, aspartame and sodium (as sodium citrate) - see section 4.4.

For a full list of excipients, see section 6.1.

3. Pharmaceutical form
Powder for oral solution.

Sachets containing the drug product, an off-white powder.

4. Clinical particulars
4.1 Therapeutic indications
For the relief of symptoms associated with colds and flu and the pain and congestion of sinusitis, including aches and pains, headache, blocked nose and sore throat, chills, lowering of temperature, and to loosen stubborn mucous and provide relief from chesty coughs.

4.2 Posology and method of administration
For oral use after dissolving the contents of the sachet in a standard mug of hot, but not boiling water (250 ml). Allow to cool to a drinkable temperature.

Adults, the elderly and children aged 12 years and over:

One sachet every four hours as required. Do not take more than 4 sachets (4 doses) in any 24 hour period.

Do not give to children under 12 years old.

4.3 Contraindications
Hypersensitivity to any of the ingredients.

Severe heart disease and cardiovascular disorders. Hypertension. Hyperthyroidism. Contraindicated in patients currently receiving or within two weeks of stopping therapy with monoamine oxidase inhibitors.

Use in patients with glaucoma or urinary retention.

Use in patients who are currently receiving other sympathomimetic drugs.

4.4 Special warnings and precautions for use
The physician or pharmacist should check that sympathomimetic-containing preparations are not simultaneously administered by several routes i.e. orally and topically (nasal, aural and eye preparations).

Care is advised in the administration of paracetamol to patients with severe renal or hepatic impairment. The hazards of overdose are greater in those with non-cirrhotic alcoholic liver disease.

Use with caution in patients with Raynaud's Phenomenon and diabetes mellitus.

Patients with prostatic hypertrophy may have increased difficulty with micturition.

Sympathomimetic-containing products should be used with great care in patients suffering from angina.

Sympathomimetic-containing products may act as cerebral stimulants giving rise to insomnia, nervousness, hyperpyrexia, tremor and epileptiform convulsions.

Patients with rare hereditary problems of fructose intolerance, glucose-gal